
oneso, artato

0 47 4 18 PCT/US99/06799

1 / 50


#### FIGURE 1





BEST AVAILABLE COPY


w)


2 / 50


















09/647418 PCT/US99/06799

#### FIGURE 9

9 / 50





10 / 50


	F,2-Casp-3							F <sub>v</sub> 2-Casp3/S163						
	Hours							Hours						
	8	4	2		.5	0	8	4	2	1	.5	0		
		1	ــــــــــــــــــــــــــــــــــــــ		<u> </u>				_			_		
100 nM	-	_							_					
500 nM	_	_	_	-	-	-	-	-	-	-				


	= <sub>v</sub> 2	-Ci	asp	-3		F <sub>v</sub> 2-Casp3/S163						
	AP1903 nM						AP1903 nM					
100	32	10	3.2	1	0	100	32	10	3.2	1	0	

12 / 50











15 / 50






"Survival	120 100 80 60 40	工工機器	T		工作的特殊的		工業機関係	<b>对欧州市山村的村村市中央</b>		<b>一种的人,但是一种的人,</b>	
Pa	0									HATT	THE STATE OF
	l-x <sub>L</sub>		<u>L</u>	+			+			+	
Construct	100 listing	M-F <sub>v</sub> 2	M-F,2-FAS	M-F,2-FAS	F <sub>pk</sub> 3	F <sub>pk</sub> 3-Casp-1	F <sub>pk</sub> 3-Casp-1	F <sub>v</sub> 2	F <sub>v</sub> 2-Casp-3	F <sub>v</sub> 2-Casp-3	Mock




0966 47418 PCT/US99/06799


18 / 50

#### 19 / 50










 $\mathbf{B}$ 



CID-Mediated Apoptosis In BPH-derived CR-2a SMC







FIGURE 22






## Fig 23 (Fig 24 on Reverse)




Final Size: 50% or 11.1cm




Dockara " artaco






Final Size: 67% or 6.9 cm


	Generation of Ad-GFP Ad-GFP- PACTrack-CMV~F	ulel — Y		99/6	367 <b>9</b> 9
0	cut pAd Trock-CMV-with ECORV+  Imp/2nd (PAd Trock-CMV) + Ind Built  + Ind FCORV+ Ind Not 7, +H20  37°C, 2frz.	Not I	h,	PAd (v	ack-CMV 9220 bp
Hall Hall Hall Hall	2) out pSH1/r - FVT S1 - YM - E with NW (got 2.2kb FVISI-)M-E)  2mg/1,2ml (pSH:/S= FVISI-YM-F+)  +2ml Bully H +H=0148ml, 376	zul EcoRI	E-Fv ev 240/3		CEst)
	Blunt:  - low M dNTP 12 wl (: 10 uM/each) + 2 w  paul H2O + 4 U/2 nl Klengw, 25°C, 3  In cativate Klengw by firsting at 75°C  (mx fine Close)  Then + 2 wl Not I, 37°C, 1 bit.	Omin: + E	DTD - 10 mm	an extra:	Tim pSH 1/s FJ/s1-YM-E TNotes + Sects
	B Run get, cut bands, paul digether, frene Clean Elute in 40 al  Digation		Frek-CAY  Lot + Eary  PSH1/2-E-	PSHVS- FV1S1	
•	Elutent 16ml + 2ml 10 x 1:20trg: Bu + 2ml Ta ligast, 16°C, evernight.	fly	Fri-Frisi -1CEST -1Not i +200 I	1304+ 	
	@ Miniprep with Dingen kit.	28			








JPEG image 511x431 pixels











Fig 30









Fig 32

Generation of Ad-GFP-CMV-TM-E Ad-GFP-CMV-E-TCE
© Co-transform E. celi BJ SIG3 with pAdEasy -1 and pAdTrack-CMV-FVISI-YM-E or pAdTrack-CMV-F-FVI-FVISI-ICG se
a. Lineazize she shuttle planmids with Pme I  1129 of pha Track-CMV-FVIsi-TME
mpAciTrack-CUIV-E-TVI-TVISI-ICEST  + 1-11 Buffer + 11-20 → 9 ul , + 1-11 Pme I
pheni-chleroform extraction, ethanol precipitation and resurpend in 6 ul H20.
B Co- leconsformation: with 100 ng DAdEcusy-1  20 ml of BJ \$183
cit 2560U, 260 Ohms, 25 aFD
pick 10 smallest colonies, miniprep. which with Pacl.
cl. Tronsfect 293 vills with Futiene.  90% confuence 293 vells in 6-well-plaite,  4 up plasmid/6 ul Futiene (well.
<u> </u>









F163S


PAd Fasg-1-Track-CMV-ICE-E 24+ 721


Fig 36





Construction of pshottle-ca and Ad-cMV-E D cut prhotli-cMV with EvoRV+NotI	-ICE	- r v.ls	1 : ICE	st	
1 mg/2 ml (pth. oflic - (MV) + 1 col Buildy Al + 1 col Fich V + 1 col Not : + H20 Soul 3000 - 2600		1 × ×	1 20 C + 1	#2 +bot I	
O art psH/S-E-FVI-FVISI-I(Est with Not I + Earl (get E-FV, -FVISI-I(Est)				•	
3 mg/4ml + 3ml Buffer H, + 3ml FroRT + H=0 21 ml, 37°C, 160					
Blust + 10 mM dNTD 18 al (10 all /2006) + 3 al Barf + 3 al H20 + 7 al T= DNA Folymianos + EDTA → 10 mm; 75°C 10°		';	انسس	h poet	
pienal: chlorofrom extraction (truice) etianal procepitation -> 24 ml Har	SI POPE TO SERVICE AND ADDRESS OF THE POPE TO SERVI		# ,	* *	# # ##
Then +3-06 Safrir # +3-06 Not I 37°C, 2002				•	-
Dar bel, at hands, politically, Garallian That in 45 1 H20					
Electronic It all total tox Lighting Baffilly					
+2 ml T4 Ligau 25°C mernight  1 Translormation					
F. Miniperp + Proposetion Engan. Checks	,				
100 ng pAd Eury-1. Miniprep + paci checkin	( ) of a min	(qarep)	oteanfor	m E.coli	1212 E31218





Fib 39




Fig 40

	1 1 1 1								
	Luciferance Assay of psimille-cmv								
	- FV,-FVSI_7CE-E 0104-010799								
v v	1 1×105 TD-201 ceils / weil (6 weil - Note)								
	in 1840 RPMT Media with 5% FOS	-							
	monter 29 hrs								
<u> </u>	) Transfection: 1: 240 pGL2 240: ICE per well								
	Frigene 2nd/4g DNA								
	inculoate 6 hrs, add AP 1903 at so nM.								
	Incubate 24 hrs.								
(3)	) lysis _ flutometer								
(દ									
(દ									
<u>.</u>									
<u>.</u>		1							
(2)	) lysis - flutoneter	1							
(2)	SAMPLE RLU % C.V.	1							
(2)	SAMPLE RLU % C.V.	1							
(2)	B JAN 99 AM 18:59 V. 1.  B JAN 99 AM 18:59 V. 1.  MEAS. TIME(s): 15.0  SAMPLE RLU % C.V.  1 1 294  1 2 291  1 2 291  MEAN 292 8.8  2 1 2681959	1							
(2)	B JAN 99 AM 18:59 V. 1.  MEAS. TIME(s): 15.0  SAMPLE RLU % C.V.  1 1 294 1 2 291 MEAN 292 8.8								
(2)	B JAN 99 AM 10:58 V. 1.  B JAN 99 AM 10:58 V. 1.  MEAS. TIME(s): 15.0  SAMPLE RLU % C.V.  1 1 294 1 2 291 1 2 291 MEAN 292 0.8  2 1 2681959 MEAN 2725979 2 2.3 Critic + PG	l 2							
(2)	B JAN 99 AM 18:59 V. 1.  B JAN 99 AM 18:59 V. 1.  MEAS. TIME(s): 15.8  SAMPLE RLU % C.V.  1 1 294 1 2 291 1 2 291 MEAN 292 8.8  2 1 2681959 MEAN 2725979 2.3 Colorl + PG	la							
(3)	B JAN 99 AM 10:58 V. 1.  B JAN 99 AM 10:58 V. 1.  MEAS. TIME(s): 15.0  SAMPLE RLU % C.V.  1 1 294 1 2 291 1 2 291 MEAN 292 0.8  2 1 2681959 MEAN 2725979 2 2.3 Critic + PG								

Fig 41

שליין פ	ing solls:	29 well - plate								
w Pitt	TD-20 - 20000/well									
			·	PDM214	sto Med	ia ( t	0/200	)		
	T-C2G	> 10000/well >	<b>4</b>				<u> </u>			
	LNCaP	-3000/well	in Indi	)MEM N	edica (t	2%FB2	. 5% Nus	zem, lan		
				. (-		11:				
•		D 29 fres		mumber	e doub	o Church	,			
		-Cz, FC2G - 48 % NCaP - 72 brev	<u>v.                                    </u>	<del>.</del> .			- 400 - 600			
	<u> </u>	NCAP = 12 2402								
<b>Q</b>	Infection:									
	For ID:	Ici 1x107 ju/ml	Tom	ł	2	4	8	16		
			Add	. 4		16	32	64 w		
		YM 2×107 zu/ml	Mol	2.5	2	10	50	40		
	<u> </u>				10	20	40	80 rd		
	-			1:10				•		
	For T-Cz	ICE 5x107zu/mi	Moi	5.2		10	30	40		
	+7-024		Add	22	4	ફ	16	3.2		
		YM 5x10724/ml		2.5		10	20	40		
-			Add	5	4	<u>&amp;</u>	16	7.5		
	Fer LH Cap			3	6	15	29	18		
	After 4 lice		sonM, inc	ubate	24 fir	٠				
			<del> </del>	· ·						
<u> </u>	Fix with 1% Glutaza idenyde -PBS, 15';									
	Stain 0.5% Courtal Violate, 20':									
	Wash wit	h H20, 30'; ith Sozoum's Sul								

oseta Braka

T-C2G Cells Treated with Ad-YAMA or Ad-ICE + AP1903 or AP20187




Fig 42

PCT/US99/06799

T-C2 Cells Treated with Ad-YAMA or Ad-ICE + AP1903 or AP 20187




Fig 43





FIG 44



Western Blot 1103-11048;

293 cells: infected with Ad-YM or Ad-ICE 9% Resolving Gel; Tonsfer-400.00A. 2 hrs. 1:1000 x-HAII - 10tAb.

1 Ad-IM3

2 - - +1403 (Benn)

3 -, + 2.D-DCB (wonM)

4 -1 + Bozin

JUI-DA Z

¿ - + 1903

7 + 2-D-DCB

8 · · + Both

9 Ail-YM4

10 -- + 1903

11- -/ +2-0-DCB

12 - + Both

Expression and Activation of Rick and YM

.





Fig 47



ffectively kill

2

+

Day 16: Inject 50 μg

C.I.D (i.p.)

## Treatment of s.c. prostate adenocarcinoma in situ with CID-inducible caspases


TRAMP-C2 cells (s.c.) Day 0: Inject 2 x 106


Day 12: Inject ~10<sup>10</sup> pfu ADV-GFP/F<sub>v</sub>2-Casp1 (i.t.)

50-100 mm<sup>3</sup>

Analysis: resect tumor, H&E, TUNEL, anti-GFP

FIG SD





## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.